Comparison of immunohistochemical and biochemical measurement of steroid receptors in primary breast cancer: Evaluation of discordant findings

Breast Cancer Research and Treatment

Volumn 50, Issue 2, 1998, Pages 125-134

  Stierer, Michael ^a   Rosen, Harald ^b   Weber, Renate ^a   Hanak, Hanns ^a   Auerbach, Leo ^c   Spona, Jürgen ^c   Tüchler, Heinz ^a  

^a HANUSCH HOSPITAL   (Austria)

^b Donauspital ^*  (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Biochemical assay; Discordant findings; Immunohistochemistry; Primary breast cancer; Steroid receptors

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; STEROID RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOCHEMISTRY; BREAST CANCER; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MEASUREMENT; MENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0031687086     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006046107249     Document Type: Article

References (59)

1. NIH Consensus Conference: Treatment of early-stage breast cancer. JAMA 265: 391-395, 1991
2. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15: 20-25, 1988
3. Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 399: 1-15, 71-85, 1992
4. Andersen J, Thorpe SM, King WJ, Rose C, Christensen JB, Rasmussen BB, Poulsen HS: The prognostic value of immunohistochemical estrogen receptor analysis in paraffin-embedded and frozen sections versus that of steroid-binding assays. Eur J Cancer 26: 442-449, 1990
5. Bezwoda WR, Esser JD, Dansey R, Kessel I, Lange M: The value of estrogen and progesterone receptor determinations in advanced breast cancer. Cancer 69: 867-872, 1991
6. Sears HF, Janus C, Levy W, Hopson R, Creech R: Breast cancer without axillary metastases: Are there high risk biologic subpopulations? Cancer 50: 1820-1827, 1982
7. Clark GM, McGuire WL: Progesterone receptors and human breast cancer. Br Cancer Res Treat 3: 157-163, 1983
8. Thorpe SM, Christensen JB, Rasmussen BB, Rose C: Short recurrence free survival associated with high estrogen receptor levels in the natural history of postmenopausal primary breast cancer. Eur J Cancer 29A: 971-977, 1993
9. De Mascarel I, Soubeyran I, MacGrogan G, Wafflart J, Bonichon F, Durand M, Avril A, Mauriac L, Trojani M, Coindre JM: Immunohistochemical analysis of estrogen receptors in 938 breast carcinomas. Appl Immunohistochem 3 (4): 222-231, 1995
10. Stierer M, Rosen H, Weber R, Hannak H, Auerbach L, Spona J, Tüchler H: A prospective analysis of immunohistochemically determined hormone receptors and nuclear features as predictors of early recurrence in primary breast cancer. Br Cancer Res Treat 36: 11-21, 1995
11. Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr Jr GH, Krook JE, Wieand HS: Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78: 764-772, 1996
12. Clark GM, Harvey JM, Osborne CK, Allred DC: Estrogen receptor status (ER) determined by immunohistochemistry (IHC) is superior to biochemical ligand-binding (LB) assay for evaluating breast cancer patients. Proc ASCO 454: 129a, 1997
13. Barnes DM, Harris WH, Smith P, Milis RR, Rubens RD: Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 74 (9): 1445-1451, 1996
14. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty Jr KS: Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res 49: 1052-1056, 1989
15. Pichon MF, Broet P, Magdelenat H, Delarue JC, Spyratos F, Basuyau JP, Saez S, Rallet A, Courriere P, Millon R, Asselain B: Prognostic value of steroid receptors after longterm follow-up of 2257 operable breast cancers. Br J Cancer 73: 1545-1551, 1996
16. Raemakers JMM, Beex LVAM, Koenders AJM: Disease free interval and estrogen receptor activity in tumor tissue of patients with primary breast cancer: analysis after long-term follow up. Br Cancer Res Treat 6: 123-130, 1985
17. Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. Eur J Cancer Clin Oncol 25: 1233-1240, 1989
18. Greene GL, Fitch FW, Jensen EV: Monoclonal antibodies to estrophilin: Probes for the study of estrogen receptors. Proc Natl Acad Sci USA 77: 157-161, 1980
19. Perrot-Applanat M, Logeat F, Croyer-Picard MT, Milgrom E: Immunocytochemical study of mammalian progesterone receptor using monoclonal antibodies. Endocrinology 116: 1473-1483, 1985
20. Kitchen PR, Stilwell RG, Henderson MA, Bennett RC, Rennie GC, Kou SJ, Georgiou T, Ayber KH: Oestrogen receptor assay of breast cancer by immunocytochemistry of fine needle aspirates. Aust NZ J Surg 61 (3): 223-228, 1991
21. Katz RL, Patel S, Sneige N, Fritsche Jr HA, Hortobagyi GN, Ames FC, Brooks T, Ordonez NG: Comparison of immunocytochemical and biochemical assays for estrogen receptor in fine needle aspirates and histologic sections from breast carcinomas. Br Cancer Res Treat 15 (3): 191-203, 1990
22. Hurlimann J, Gebhard S, Gomez F: Estrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas. Histopathology 23: 239-248, 1993
23. Esteban J, Battifora H, Warsi Z, Bailey A, Bacus S: Quantification of estrogen receptors on paraffin-embedded tumors by image analysis. Mod Pathol 4: 53-57, 1991
24. Pari FP, Posey YF: Discrepancies of the biochemical and immunohistochemical estrogen receptor assays in breast cancer. Hum Pathol 129: 960-966, 1988
25. Beck TH, Pollow K, Grill HJ, Weikel W, Kreienberg R: Hormonrezeptornachweis der Mammakarzinome: Additive Informationen immunhistochemischer und histologischer Untersuchungen zum biochemischen Rezeptorassay. Tumor Diagnostik Therapie 10: 104-108, 1989
26. Allegra JC, Lippmann ME, Green L, Barlock A, Simon R, Thompson EB, Huff KK, Griffin W: Estrogen receptor values in patients with benign breast disease. Cancer 44: 228-231, 1979
27. Mohammed RH, Laktatua DJ, Hans E, Yashineh WJ: Estrogen and progesterone receptors in human breast cancer. Cancer 58: 1076-1081, 1986
28. EORTC Breast Cancer Cooperative Group: Revision of the standards for the assessment of hormone receptors in human breast cancer. Eur J Cancer Clin Oncol 16: 1513-1515, 1980
29. Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptornachweis (ER-ICA) im Mammakarzinomgewebe. Pathologie 8: 138-140, 1987
30. Neumann K, Rüschoff J, Horstmann A, Zwiorek L, Kalbfleisch H: Hormonrezeptorgehalt von Mammakarzinomen - Vergleich morphologischer und biochemischer Bestimmungsmethoden. Pathologie 10: 160-164, 1989
31. UICC (International Union against Cancer): TNM classification of malignant tumors (3rd ed.). UICC, Geneva, 1979, p 4754
32. WHO: THe World Health Organization histological typing of breast tumors (2nd ed.). Am J Clin Pathol 78: 806-816, 1982
33. Bloom HJG, Richardson WW: Histological grading and prognosis in breast carcinoma. Br J Cancer 11: 359-377, 1957
34. Fentiman IS: Risk factors for benign breast disease. In: Smallwood JA, Taylor I (eds) Benign Breast Disease. Urban & Schwarzenberg, 1990, p 129
35. Press MR, Schwartz AM: Prognostic markers in breast cancer: laboratory analysis of breast biopsies. United States and Canadian Academy of Pathology, San Francisco, 1994
36. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor and patient characteristics in human breast cancer. J Clin Oncol 102: 1102-1109, 1984
37. Saez S, Martin PM, Chouvet CD: Estradiol and progesterone levels in human breast adenocarcinoma in relation to plasma estrogen and progesterone levels. Cancer Res 38: 3468-3474, 1978
38. Barrett-Lee PJ, Travers MT, McClelland RA, Lugmani Y, Coombes RC: Characterization of estrogen receptor messenger RNA in human breast cancer. Cancer Res 47: 6653-6659, 1987
39. Pertschuk LP, Feldman JG, Eisenberg KB, Carter AC, Thelmo WL, Cruz WP, Thorpe SM, Christensen IBJ, Rasmussen BB, Rose C, Greene G: Immunocytochemical detection of progesterone receptor in breast cancer with monoclonal antibody. Relation to biochemical assay, disease free survival and clinical endocrine response. Cancer 62: 342-349, 1988
40. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M, Jakesz R: Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res 50: 7057-7061, 1990
41. Perrot-Applanat M, Groyer-Picard MT, Lorenzo F, Jolivret A, Vu Hai MT: Immunocytochemical study with monoclonal antibodies to progesterone receptor in human breast tumors. Cancer Res 47: 2652-2661, 1987
42. Helin H, Isola J, Helle M, Koivula T: Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. Br J Cancer 62: 109-112, 1990
43. Westphal HM, Mugele K, Beato M: Immunochemical characterization of wild-type and variant glucocorticoid receptors by monoclonal antibodies. EMBO J 3: 1493-1499, 1984
44. King WJ, DeSombre ER, Jensen EV: Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors. Cancer Res 45: 293-296, 1985
45. Jakesz R, Smith CA, Aitken S: Influence of cell proliferation and cell cycle phase on expression of estrogen receptor in MCF-7 breast cancer cells. Cancer Res 44: 619-622, 1984
46. Horwitz KB, McGuire WL, Segaloff OH: A predictive response to endocrine therapy in human breast cancer. A hypothesis. Science 5: 428-433, 1975
47. Graham II ML, Smith JA, Jewett PB, Horwitz KB: Heterogeneity of progesterone receptor content and remodeling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res 52: 593-602, 1992
48. Markopoulos C, Berger UTA, Wilson P, Gazet JC, Coombes RC: Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle. Br Med J 296: 1349-1353, 1988
49. Khan SA, Rogexs MA, Obando JA, Tamsen A: Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 54: 993-997, 1994
50. Azzopardi J: Problems in breast pathology. In: Major Problems in Pathology. Vol. II, WB Saunders, 1987, pp 23-24
51. Sarrif AM, Durant JR: Evidence that estrogen-receptor-negative, progesterone-receptor-positive breast and ovarian carcinomas contain estrogen receptor. Cancer 48: 1215-1218, 1981
52. Greene GL, Sobel NB, King WJ: Immunochemical studies of estrogen receptors. J Steroid Biochem 20: 51-57, 1984
53. Pertschuk LP, Kim DS, Nayer K, Feldman JG, Eisenberg BK, Carter AC, TianRong Z, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Cancer 66: 1663-1670, 1990
54. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz Jr AB: Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. Arch Surg 125: 107-113, 1990
55. Esteban JM, Ahn C, Mehta P, Battifora H: Biological significance of quantitative estrogen receptor immunohistochemical assay by image analysis in breast cancer patients. Am J Clin Pathol 102: 9-12, 1994
56. Al Saati T, Clamens S, Cohen-Knafo E, Faye JC, Prats H, Coindre JM, Wafflart J, Caveriviere L, Bayard F, Delsol G: Production of monoclonal antibodies to human oestrogen receptor protein (ER) using recombinant ER (RER). Int J Cancer 55: 651-654, 1993
57. Taylor CR, Shi S, Chaiwun B, Young L, Ashraf Imam S, Cote RJ: Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections. Hum Pathol 25: 263-270, 1994
58. Allred DC: Should immunohistochemical examination replace biochemical hormone receptor assays in breast cancer? Am J Clin Pathol 99: 1-3, 1992
59. Battifora H, Mehta P, Ahn C, Esteban JM: Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunochem 1: 36-45, 1993